NAD+ IV Therapy

Strong mechanistic basis from longevity research. Clinical evidence growing for addiction, fatigue, and cognitive function. Large RCTs pending. UPDATE (August 2026): A Nature Aging 2026 meta-analysis of >15,000 human methylation profiles across 17 tissues identified a modifiable, NAD+-metabolism-linked gene cluster distinct from age-associated clusters that beneficial interventions fail to move, which the authors present as support for NAD+ as a therapeutic target in aging. This strengthens the mechanistic rationale for the NAD+ axis generally. It says nothing about route of administration, and there remains no peer-reviewed human evidence that intravenous NAD+ outperforms oral precursors or improves any aging outcome. Large RCTs remain absent. UPDATE (September 20, 2026): The most consequential NAD+ development this cycle is about MEASUREMENT, and it is peer-reviewed. Nature Metabolism 2026;8:1282-1290 (Tretowicz, Scantlebery, Schomakers et al.; Houtkooper lab, Amsterdam UMC, Brief Communication, 14 May 2026) quantified NAD+ across SEVEN independent human cohorts using a rigorously validated UHPLC-high-resolution mass spectrometry method built to account for real-world analytical variability. Whole-blood NAD+ was remarkably STABLE with chronological age and UNCHANGED by lifestyle interventions - while rising, as expected, with nicotinamide riboside supplementation. The authors' stated conclusion is that this challenges the utility of blood NAD+ as a biomarker of ageing or of lifestyle. The methodological substance is that much of the age-related blood NAD+ decline reported in the prior literature is plausibly assay variability rather than biology. Read precisely: this does NOT refute tissue-level or intracellular NAD+ decline, does NOT refute NAD+ precursor pharmacology, and does NOT overturn the mechanistic NAD+ rationale summarised above. What it does overturn is the practice of using a blood NAD+ value as a biological-age readout or as a justification for infusion therapy - and it means a post-treatment rise in blood NAD+ demonstrates delivery, not benefit. Counterweight, also peer-reviewed: GeroScience 2026 (Itabashi Longitudinal Study on Aging, 16 Sept 2026) found that among 529 community-dwelling Japanese adults aged 65+, the 32 participants (6.0%) meeting revised J-CHS frailty criteria had LOWER median whole-blood NAD+ than non-frail participants, surviving adjustment for age, sex and fasting time with spline, Firth penalised-likelihood and haematological sensitivity analyses. That is the clearest human link yet between circulating NAD+ and a functional phenotype - but it is cross-sectional with only 32 frail participants, reverse causation is unaddressed (frailty itself reduces activity and intake), and it provides no evidence that raising NAD+ reduces frailty. Net position for IV NAD+ is unchanged and, if anything, weaker on the monitoring side: still no peer-reviewed human evidence that intravenous NAD+ outperforms oral precursors or improves any aging outcome, and now no defensible basis for tracking response with a blood NAD+ level.

Evidence Scale